Swedish Orphan Biovitrum (BIOVF) Set to Post Quarterly Earnings on Tuesday

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) is expected to post its results before the market opens on Tuesday, October 27th. Analysts expect Swedish Orphan Biovitrum to post earnings of $0.62 per share and revenue of $890.88 million for the quarter.

Swedish Orphan Biovitrum Price Performance

OTCMKTS BIOVF opened at $45.72 on Monday. The business has a fifty day moving average price of $46.31 and a 200 day moving average price of $46.50. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88. The company has a market cap of $16.27 billion, a P/E ratio of 101.59 and a beta of 0.47. Swedish Orphan Biovitrum has a one year low of $34.88 and a one year high of $49.03.

Analysts Set New Price Targets

BIOVF has been the subject of a number of research reports. Nordea Equity Research lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday. Pareto Securities downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options.

Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements.